Supriya Lifescience Ltd (SUPRIYA) — FY26 Annual Report | 1 September 2026

Supriya Lifescience Ltd. reported FY25-26 revenue of [amount context mismatch] crore, up from ₹697 crore in FY25, with EBITDA margin at 36.85% and ROCE at 22.38%. The company achieved its highest-ever revenue and EBITDA, driven by growth in anti-histamines (₹76.13 crore, +9.5% YoY), vitamins ([amount not verified], +12.3% YoY), anti-asthmatics (₹46.15 crore, +5.7% YoY), and analgesics (₹28.14 crore, +3.5% YoY). Strategic focus includes backward integration (76% of revenue), expansion of manufacturing capacity at Ambernath and Patalganga, and a 10-year €600 million CMO contract contributing from FY27. The company targets ₹1,000 crore revenue by FY27 while maintaining healthy margins. Exports contributed 82% of revenue, with key markets in Europe (40%), US, Japan, and Latin America. The Board approved re-appointments of Dr. Saloni Satish Wagh and Ms. Shivani Satish Wagh, both with 10 directors total, including 1 woman independent director. No material changes affected financial position post-year-end. The filing confirms compliance with SEBI, Companies Act, and CSR norms, with ₹5.09 crore spent on CSR initiatives. The AGM is scheduled for September 24, 2026, via video conferencing, with dividend payment on or after that date.